Title page (Major article)

SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2

Running title: T cell and humoral immune responses to BNT162b2 vaccine

Word counts of Abstract: 197 words

Word counts of text: 3214 words

Authors:

Junko S. Takeuchi*[1], Ami Fukunaga*[2], Shohei Yamamoto*[2], Akihito Tanaka[3], Kouki Matsuda[4], Moto Kimura[1], Azusa Kamikawa[1], Yumiko Kito[1], Kenji Maeda[4], Gohzoh Ueda[5], Tetsuya Mizoue[2], Mugen Ujiie[6], Hiroaki Mitsuya[4], Norio Ohmagari[6], Wataru Sugiura[7]

Affiliations:

[1] Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

[2] Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

[3] Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo 162-8655, Japan

[4] Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

[5] Division of Core Diagnostics, Abbott Japan LLC, Tokyo 108-6305, Japan

[6] Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

[7] Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

*Equal contribution as first author

Corresponding Author

Wataru Sugiura

Center for Clinical Sciences, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan

TEL: +81-3-3202-7181, Fax: +81-3-5273-6850

E-mail: wsugiura@hosp.ncgm.go.jp

Abstract

Background. The humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon coronavirus disease 2019 (COVID-19) vaccination remain to be clarified. Hence, we aimed to investigate the chronological changes in SARS-CoV-2 specific IgG antibody, neutralizing antibody, and T cell responses during and after receiving the BNT162b2 vaccine.

Methods. We performed serological, neutralization, and T cell assays among 100 hospital workers aged 22-73 years who received the vaccine. We conducted five surveys on day 1, day 15, day 29 (seven days after the second dose), day 61, and days 82–96 following the first dose.

Results. SARS-CoV-2 spike protein-specific IgG (IgG-S) titers and T cell responses increased significantly following the first vaccination dose. The highest titers were observed on day 29 and decreased gradually until the end of the follow-up period. There was no correlation between IgG-S and T cell responses. Notably, T cell responses were detected on day 15, earlier than the onset of neutralizing activity.

Conclusions. This study demonstrated that both IgG-S and T cell responses were detected before acquiring sufficient levels of SARS-CoV-2 neutralizing antibodies. These early immune responses are sustained for approximately six–ten weeks following the second vaccination dose.

54 ***Keywords.*** SARS-CoV-2, COVID-19, BNT162b2 vaccine, humoral immunity, T cell immunity,

55 neutralizing antibody

56

BACKGROUND

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has imposed a tremendous burden on global morbidity and mortality since December 2019 [1]. In response to the COVID-19 pandemic, multiple vaccines have been rapidly developed and tested for their efficacy and safety. BNT162b2, an mRNA-based SARS-CoV-2 vaccine (Pfizer-BioNTech), was the first COVID-19 vaccine listed for emergency use and COVAX roll-out by the World Health Organization, with a 95% efficacy in clinical trials [2]. To examine the effectiveness of the vaccine, a growing body of studies has investigated SARS-CoV-2 specific humoral and cellular responses following vaccination. Studies have shown that a two-dose regimen of BNT162b2 induces SARS-CoV-2 specific humoral and cellular responses, such as immunoglobulin G (IgG) antobodies [3-5], neutralizing antibodies [6-8], as well as $CD4^+$ and $CD8^+$ T cells [6, 7, 9].

However, some important issues remain to be addressed. First, little is known about neutralizing antibodies and cellular immune responses against SARS-CoV-2 following COVID-19 vaccination compared to the evidence on IgG antibodies. Second, epidemiological evidence on temporal changes in humoral and cellular responses and their associated factors, and use of longitudinal data with repeated measures, is limited. Third, studies on the correlation between humoral and cellular responses are scarce. Investigation of humoral and

75 cellular immune responses during and after the COVID-19 vaccination regimen is required to
76 understand its effectiveness, the duration of effectiveness, and the differences in such
77 responses across varying background factors.
78 Hence, this longitudinal study aimed to investigate chronological changes in IgG
79 antibody, neutralizing antibody, and T cell responses, along with their associated factors, during
80 and after the BNT162b2 vaccination regimen, in hospital workers of a national medical
81 institution in Japan.
82
83 **METHODS**
84 ***Study Design and Participants***
85 We performed a longitudinal study among the staff of the National Center for Global Health and
86 Medicine (NCGM), a national medical institution designated for research and treatment of
87 infectious diseases, between March and June 2021, after the start of the vaccination program.
88 We recruited 100 volunteers via e-mail from NCGM staff aged 20 years or above who were
89 scheduled to receive the first COVID-19 vaccination dose on the dates of the baseline survey.
90 None of the participants were on immunosuppressive medication or had a history of COVID-19.
91 All participants received the mRNA-based SARS-CoV-2 vaccine BNT162b2 (Pfizer-BioNTech)
92 according to the standard protocol (two doses of 30 μg administered three weeks apart) [6, 10].

A total of five surveys were conducted on the following schedule: day 1 (immediately after the first dose), day 15, day 29 (seven days after the second dose), day 61, and days 82-96 (at the time of periodic health checkup). The study protocol was approved by the Ethics Committee of NCGM, Japan (approval number: NCGM-A-004175-00). Written informed consent was obtained from all the participants before the baseline survey.

Cells and Viruses

VeroE6$_{TMPRSS2}$ cells [11] were obtained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank (Osaka, Japan). VeroE6$_{TMPRSS2}$ cells were maintained in DMEM supplemented with 10% FCS, 100 μg/mL penicillin, 100 μg/mL streptomycin, and 1 mg/mL G418. The SARS-CoV-2 NCGM-05-2N strain (SARS-CoV-2$_{05\text{-}2N}$) was isolated from the nasopharyngeal swab of a patient with COVID-19 admitted to the NCGM hospital [8, 12].

Serological Assays

We performed three serological assays to detect the IgM and IgG antibodies against SARS-CoV-2 spike protein (IgM-S and IgG-S, respectively) and IgG antibodies against SARS-CoV-2 nucleocapsid protein (IgG-N). The presence of IgG-N antibodies can indicate SARS-CoV-2 infection prior to the study and during follow-up, regardless of the vaccination status. In

111 contrast, the presence of IgM-S and IgG-S indicates the previous infection and/or humoral
112 immunity following vaccination, because BNT162b2 is constructed to express the full-length
113 spike protein.

114 To detect IgG-S, the AdviseDx SARS-CoV-2 IgG II assay was performed using the
115 Abbott ARCHITECT® following the manufacturer's protocol. The assay detects the IgG
116 antibodies against the receptor-binding domain (RBD) of the S1 subunit of the SARS-CoV-2
117 spike protein using chemiluminescent microparticle immunoassay (CMIA). The resulting
118 chemiluminescence in relative light units (RLU) indicates the strength of the response, which in
119 turn reflects the quantity of IgG-S present. We considered 50 AU/mL and above as the cutoff for
120 seropositivity, as recommended by the vendor. We also tested 4160 AU/mL as the cutoff, given
121 that this threshold may correspond to a 95% probability of sufficient neutralizing activity [13].
122 This quantitative IgG-S test could evaluate an individual's humoral response to vaccines.

123 To detect IgM, the AdviseDx SARS-CoV-2 IgM assay, based on semi-quantitative
124 CMIA, was performed using the Abbott ARCHITECT® according to the manufacturer's
125 instructions. We defined the seropositive cutoff as 1.0 (index value) and above, according to the
126 vendor's recommendation.

127 For the IgG-N assay, the Abbott ARCHITECT® SARS-CoV-2 anti-N IgG assay based

128 on semi-quantitative CMIA was performed. We considered the index values of 1.40 and above

129 as seropositive cutoff according to the manufacturer's instructions.

130

131 ***Neutralization Assay***

132 An enzyme-linked immunosorbent assay (ELISA)-based semi-quantitative neutralization assay

133 was performed at a single serum dilution according to the manufacturer's instructions (SARS-

134 CoV-2-NeutraLISA, Euroimmun, Germany). Antibody-mediated inhibition of soluble human

135 receptor protein (angiotensin-converting enzyme 2, hACE2) binding to the RBD of the viral S1

136 region was tested. The surrogate neutralizing capacity was calculated as the percentage of

137 inhibition (% IH): IH = 100% - (extinction of the respective sample × 100% / extinction of the

138 blank). An IH<20% was considered as negative, IH ≥20% to <35% intermediate, and IH ≥35%

139 positive. Each serum sample was tested in duplicates.

140 The in vitro viral experiment-based neutralizing activity was determined

141 by quantifying the serum-mediated suppression of the cytopathic effect (CPE) of the SARS-

142 CoV-2 strain in $VeroE6_{TMPRSS2}$ cells, as previously described [8], but with minor modifications. In

143 brief, each serum was four-fold serially diluted in the culture medium. The diluted sera were

144 incubated with 100 $TCID_{50}$ (50% tissue culture infectious dose) of viruses at 37 °C for 20 min.

145 Then, the serum-virus mixtures were inoculated into $VeroE6_{TMPRSS2}$ cells (1.0×10^4/well) in 96-

146 well plates. After culturing the cells for three days, the CPE levels observed in SARS-CoV-2-

147 exposed cells were determined by the WST-8 assay using the Cell Counting Kit-8 (Dojindo,

148 Kumamoto, Japan). The serum dilution that resulted in 50% inhibition of CPE was defined as a

149 50% neutralization titer (NT_{50}). Each serum sample was tested in duplicates.

150

151 ***IFN-γ Whole Blood Assay***

152 SARS-CoV-2 specific $CD4^+$ and $CD8^+$ T cell responses were investigated on days 1, 15, 29, and

153 61. We quantified T cell-produced interferon-gamma (IFN-γ) in response to SARS-CoV-2 spike

154 peptides using QuantiFERON SARS-CoV-2 RUO (QIAGEN, Germany) according to the

155 manufacturer's instructions. Briefly, 5 mL of whole blood specimens were collected in a

156 collection tube containing sodium heparin (VP-H050K, Terumo, Japan) at four time points

157 during the vaccination regimen. The collected blood samples were stored at room temperature

158 for no more than 2–3 h, and 1 mL of the sample was transferred to each QuantiFERON blood

159 collection tube: Nil (negative control), mitogen (positive control), Ag1 and Ag2 (spike protein

160 antigens). Ag1 induces a $CD4^+$ T cell response, and Ag2 stimulates both CD4+ and CD8+ T cell

161 responses. The four tubes were inverted to coat the sides of the tubes and placed in a 37 °C

162 incubator for 16–24 h. Subsequently, the plasma samples were harvested following

163 centrifugation, stored at -80 °C, and tested for the release of IFN-γ from stimulated T cells by

164 QuantiFERON ELISA with microplate reader SpectraMax iD5 (Molecular Devices, USA). The

165 quantitative IFN-γ concentration (IU/mL) was analyzed using the QuantiFERON R&D Analysis

166 Software (version 5.3.0). Greater than or equal to 0.20 IU/mL IFN-γ concentration was used to

167 define positive T cell responses, as previously reported [14].

168

169 ***Statistical Analysis***

170 To examine the difference in change of IgG-S titers across background factors (age, sex, and

171 body mass index [BMI]), we fitted the mixed model of repeated measures with an unstructured

172 covariance matrix. Background factors were treated as categorical variables in the models: age

173 (<40 or ≥40 years), sex (men or women), and BMI (<25 or ≥25 kg/m^2). Log_{10}-transformed IgG-

174 S titer was used as the dependent variable. We set each background factor, time, and interaction

175 terms as fixed factors, and individual identifiers and time as random factors in the model. In all

176 models, we adjusted for age and sex as covariates. We estimated the mean log_{10}-transformed

177 IgG-S titer with 95% confidence intervals (CIs); then, we back-transformed them and presented

178 them as geometric means titer. To compare the mean differences of IgG-S titers between

179 background factors at each time point, we used the Wald test with Bonferroni adjustment. As

180 three participants received their second vaccination on an irregular schedule (more than four

weeks after the first dose), we treated their antibody titer data of day 29 and day 61 as missing values. We repeated these analyses for spike-specific T cell responses.

To examine the correlation between IgG-S titers and spike-specific T cell responses at each time point (days 1, 15, 29, and 61), we conducted Spearman's rank correlation test.

Statistical analyses were conducted using STATA version 17.0.

RESULTS

Study participants

All participants (n=100) completed the surveys as planned, except for one who did not attend the last survey. Table 1 presents their background information. The participants included 32 men and 68 women with a mean age (standard deviation) of 42.7 (11.7) years (range: 22–73 years). Major occupations included administrative staff (19%), nurses (17%), doctors (7%), allied healthcare professionals (4%), and other occupations (e.g. researchers and research assistants) (53%).

Antibody Titers and Neutralizing Activity

Table 2 and Figures 1–2 show the humoral and cellular responses during and after the vaccination regimen. All participants were seronegative for IgG-S, IgG-N, and IgM on day 1

(Figure 1A–C). These observations were consistent with the fact that none of the participants had a history of COVID-19. IgG-S titers were significantly higher than the baseline value in the later time points (Table 2). We observed the highest IgG-S titers on day 29 (seven days after the second dose), with a median of 20,582 AU/mL (interquartile range [IQR] 11,711–29,650), followed by a time-dependent decrease: median of 9649 (IQR 5189–13,141) on day 61 and 5539 (IQR 2954–8324) on days 82–96. For IgG-S, 99% (99/100) of the participants were seropositive on day 15 following the first dose, and all participants were seropositive on day 29 (seven days after the second dose) and remained positive during follow-up until days 82–96. Regarding the neutralizing activity defined by the IgG-S titers (cutoff of 4160 AU/mL), no participants were seropositive on day 15, while 96% became positive on day 29; this decreased to 81% and 59% on day 61 and days 82–96, respectively (Table 2). We also tested neutralizing activity using the ELISA-based semi-quantitative neutralization assay, which showed that 37% of the participants had sufficient neutralizing activity on day 15, while all participants had sufficient levels of neutralizing activity on day 29 and 61 (Table 2 and Figure 1D).

There was a significant association of younger age (<40 years) with higher IgG-S titers throughout the five survey time points ($P<0.01$) (Table 3). Although we did not observe a statistically significant difference in IgG-S titers with respect to sex or BMI, females or individuals with normal BMI tended to have higher IgG-S titers than males or those with BMI

217 ≥25 kg/m^2 throughout the surveys.

218

219 ***Vaccine-Induced T cell Responses***

220 None of the participants had T cell responses against SARS-CoV-2 antigens on day 1, indicating

221 that none of them were infected with SARS-CoV-2 prior to the study. Following the first

222 vaccination dose, T cell responses increased (0.85 and 1.72 IU/mL for Ag1-Nil and Ag2-Nil,

223 respectively) and peaked after the boost on day 29 (5.40 and 9.40 IU/mL for Ag1-Nil and Ag2-

224 Nil, respectively), but decreased on day 61 (1.54 and 2.76 IU/mL for Ag1-Nil and Ag2-Nil,

225 respectively) (Table 2 and Figure 2). Overall, higher values for T cell response were obtained

226 for Ag2-Nil (CD4$^+$ and CD8$^+$) than Ag1-Nil (CD4$^+$), indicating that both CD4$^+$ and CD8$^+$ T cells

227 serve as cellular immunity induced by the COVID-19 vaccination.

228 While analyzing the association between background factors (age, sex, and BMI) and

229 T cell responses, we did not observe a statistically significant difference in IFN-γ produced by T

230 cells by age or BMI at all time points (data not shown). While men were significantly associated

231 with a higher IFN-γ production by CD4$^+$ T cells on day 29 (P <0.05), this association was not

232 observed when one high outlier was excluded (Supplementary Figure 1).

233 Further, we found no correlations between IgG-S and IFN-γ production in CD4$^+$

234 (Figure 3A) and CD4$^+$ + CD8$^+$ T cells throughout the surveys, except on day 15, and

significantly weak correlations were observed on day 15 (Spearman rank coefficient [rho] = 0.38; $p < 0.01$ and rho = 0.29; $p < 0.01$ for $CD4^+$ and $CD4^+ + CD8^+$, respectively) (Figure 3B).

DISCUSSION

In this study, we documented the IgG-S antibody and T cell responses on day 15 following the first dose of the BNT162b2 vaccine. We found that both IgG-S antibody and T cell responses peaked seven days after the second dose (day 29) and gradually declined until the end of the follow-up period. Sufficient levels of the IgG-S antibody were maintained for over six to ten weeks following the second dose of BNT162b2 vaccination. It is noteworthy that T cell responses were detected earlier than the neutralizing activity. However, we did not observe any clear correlation between humoral and cellular immune responses throughout the survey period.

We observed that IgG-S titers on day 15 and day 29 were 211-fold and 7916-fold higher, respectively, than that of baseline, and it decreased by 53.1% and 73.1% on day 61 (39 days after the second dose) and days 82-96 (60-74 days after the second dose), respectively, compared to the peak on day 29. Nevertheless, IgG-S titers remained seropositive among all participants until the end of the follow-up period. Similar to our findings on chronological changes in IgG-S titers, a multicenter prospective study among health care professionals at multiple time points (days 0, 14, 28, 42, 56, and 90) showed that the antibody response

253 (measured as IgG-S) was detected on day 14 following the first dose and reached a peak
254 between days 14 and 28 (the second dose was administered on day 21). Further, the response
255 decreased by 43% on day 90 compared to the highest antibody response, while all participants
256 had detectable responses until the end of the follow-up [3].

257 In contrast to the IgG-S antibody response, the majority of participants did not attain
258 sufficient levels of neutralizing antibodies against SARS-CoV-2 on day 15, as assessed by
259 ELISA-based neutralization assay (37%) and IgG-S titers with a cutoff of 4160 AU/mL (0%).
260 However, nearly 100% of participants were positive for neutralizing activity in both assays on
261 day 29. These results suggest that individuals might attain sufficient neutralizing antibodies
262 against SARS-CoV-2 seven days after the second dose of the BNT162b2 vaccine. Further
263 investigations should be tested in neutralizing activity for a longer follow-up time period, given
264 that the proportion of those with sufficient neutralizing antibodies declined after the peak when
265 it was assessed with IgG-S titers.

266 Furthermore, we showed that younger age was associated with higher IgG-S titers
267 throughout the follow-up period. This finding accords with previous studies that showed an
268 association between age and antibody responses [5, 15, 16]. It has been suggested that age is an
269 important contributing factor for vaccine-induced humoral immune responses. Similarly, our
270 findings and previous evidence suggest that older individuals are vulnerable to lower IgG-S

271 titers throughout and after COVID-19 vaccination compared to younger individuals.

272 Our study showed that T cell responses were detected on day 15 following the first
273 dose of the vaccination, similar to the antibody responses. This early induction of T cell
274 responses agrees with the findings of a cohort study of 20 Singapore healthcare workers who
275 received the BNT162b2 vaccine [7], and a study of individuals who received the Moderna
276 mRNA-1273 vaccine [14]. Notably, we observed that T cell responses were detectable earlier
277 than the neutralizing antibodies, consistent with a previous report [7]. A clinical trial evaluating
278 the efficacy of BNT162b2 indicated that the vaccine might prevent the onset of COVID-19
279 approximately 12 days after the first dose [10]. These observations suggest that early T cell
280 responses, detected on day 15 and earlier than neutralizing antibodies, may contribute to the
281 vaccine's efficacy. Interestingly, early T cell responses have also been reported in COVID-19
282 cases. A review paper by Bertoletti et al. suggested that T cells are detected within 7–10 days
283 after infection [17]. Moreover, early induction of IFN-γ-producing SARS-CoV-2-specific T cells
284 was observed in patients with mild symptoms [18]. Rapid and functional induction of T cell
285 immune responses may play a critical role in both COVID-19 cases and vaccinated individuals.

286 However, we did not find any evidence of an association between background factors
287 (age, sex, and BMI) and T cell responses. A recent study reported that the production of IFN-γ
288 from SARS-CoV-2 spike-specific T cells was lower in older vaccinated participants (≥ 80 years

289 old) [19]. In our study, all participants were younger than 80 years old (the maximum age was
290 73 years), which might explain the null finding on the association between age and T cell
291 responses.

292 Furthermore, we did not find any correlation between IgG-S and IFN-γ production in
293 $CD4^+$ and $CD4^+$ + $CD8^+$ T cells. Some participants had higher IFN-γ values with low or
294 moderate IgG-S levels and vice versa. However, the correlation between SARS-CoV-2 spike-
295 specific humoral and cellular immune responses remains controversial [7, 20]. This discrepancy
296 can be explained by the pre-existence of cross-reactive memory T cells against SARS-CoV-2.
297 Interestingly, previous studies have reported that long-lasting memory T cells, induced by
298 common cold coronaviruses, can display robust cross-reactivity to SARS-CoV-2 [21, 22].
299 However, the participants in this study did not show T cell responses against SARS-CoV-2 spike
300 antigens on day 1, implying that none of the participants had pre-existing cross-reactive
301 memory T cells against SARS-CoV-2.

302 The strengths of the present study include the longitudinal design with repeated
303 measures of antibodies and T cell responses during and after the COVID-19 vaccination
304 regimen. However, this study has several limitations. First, our study was conducted in a small-
305 scale cohort of hospital workers in a single medical institution in Japan; thus, our findings might
306 not be generalized to other settings. Second, the sufficient level of neutralizing activity or

cellular immunities that is enough to protect against SARS-CoV-2 infection is not well known. In this study, sufficient neutralizing activity levels were defined as IH ≥35% in ELISA-based semi-quantitative neutralization assay (NeutraLISA), and the positive results evaluated by NeutraLISA spanned a wide range of values when the samples were analyzed by an in vitro virological experiment (summarized in Supplementary Figure 2). Further studies are warranted to determine sufficient levels of SARS-CoV-2 IgG antibody, neutralizing antibody, and T cell responses against SARS-CoV-2 infection and the duration of immunity induced by the vaccine.

In conclusion, our study demonstrated that BNT162b2 vaccination induces SARS-CoV-2 specific IgG-S antibody and T cell responses, which were detected on day 15 following the first dose and peaked after the second dose and gradually declined over time. Sufficient levels of these responses against SARS-CoV-2 infection were maintained for over six–ten weeks following the second dose of BNT162b2 vaccination, and these responses were detected earlier than the onset of neutralizing activity. Our study contributes to a better understanding of the humoral and cellular immune responses upon COVID-19 vaccination.

Footnote page

***Role of the Funder/Sponsor*.** The funders did not play any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Funding. This work was funded by Abbott Japan (grant number 20C050), the NCGM COVID-19 Gift Fund (grant number 19K059), the Japan Health Research Promotion Bureau Research Fund (grant number 2020-B-09), and a grant from the National Center for Global Health and Medicine (grant number 21A006).

Acknowledgments. We thank the members of the study group (Yusuke Oshiro, Natsumi Inamura, Takashi Nemoto, Haruka Osawa, Maki Konishi, and Nobumi Katayama) for their support.

Conflict of Interests. The authors (except Gohzoh Ueda) declare no conflict of interest. Gohzoh Ueda is one of employees of Abbott Japan, which provided the antibody assay reagents and funding for the present study. The Role of the funder/sponsor is described above.

References:

1. WHO Coronavirus Disease (COVID-19) Dashboard. Available at: https://covid19.who.int/. Accessed July 06 2021.

2. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med **2021**; 384:1412-23.

3. Favresse J, Bayart JL, Mullier F, et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect **2021**; 10:1495-8.

4. Zaffina S, Alteri C, Ruggiero A, et al. Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers. J Virus Erad **2021**; 7:100046.

5. Kageyama T, Ikeda K, Tanaka S, et al. Antibody responses to BNT162b2 mRNA COVID-19 vaccine in 2,015 healthcare workers in a single tertiary referral hospital in Japan. medRxiv **2021**:2021.06.01.21258188.

6. Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature **2021**.

7. Kalimuddin S, Tham CYL, Qui M, et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med (N Y) **2021**; 2:682-8 e4.

8. Maeda K, Amano M, Uemura Y, et al. Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated

Individuals. medRxiv **2021**:2021.07.27.21261237.

9. Martínez-Gallo M, Esperalba-Esquerra J, Pujol-Borrell R, et al. T-cell responses as a correlate of COVID-19 vaccination. A pilot study in Health Care Workers. medRxiv **2021**:2021.03.31.21254472.

10. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med **2020**; 383:2603-15.

11. Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A **2020**; 117:7001-3.

12. Maeda K, Higashi-Kuwata N, Kinoshita N, et al. Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma. Sci Rep **2021**; 11:5563.

13. Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med **2021**; 27:981-4.

14. Jaganathan S, Stieber F, Rao S, et al. Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals: Research Square, **2021**.

15. Muller L, Andree M, Moskorz W, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis **2021**.

16. Terpos E, Trougakos IP, Apostolakou F, et al. Age-dependent and gender-dependent

antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am J Hematol **2021**; 96:E257-E9.

17. Bertoletti A, Tan AT, Le Bert N. The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. Oxford Open Immunology **2021**; 2.

18. Tan AT, Linster M, Tan CW, et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep **2021**; 34:108728.

19. Collier DA, Ferreira I, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature **2021**; 596:417-22.

20. Parry HM, Bruton R, Tut G, et al. Single Vaccination with BNT162b2 or ChAdOx1 in Older People Induces Equivalent Antibody Generation but Enhanced Cellular Responses after ChAdOx1. SSRN Electronic Journal **2021**.

21. Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science **2020**; 370:89-94.

22. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell **2020**; 181:1489-501 e15.

Figure Legends

Figure 1. Humoral responses during and after BNT162b2 mRNA-based SARS-CoV-2 vaccination regimen. (A-C) Humoral responses in serum on day 1 (immediately after the first dose), day 15, day 29 (seven days after the second dose), day 61, and days 82–96 (noted as day 90). IgG antibodies against SARS-CoV-2 spike protein (A), nucleocapsid (B), and IgM against spike protein (C) were measured using chemiluminescent microparticle immunoassay (CMIA). An ELISA-based semi-quantitative neutralization assay was also performed (D). Box plots show median and two-thirds extended widths of interqurtile range (IQR). Dots represent outliers (more/less than two-thirds extended widths of IQR). Dashed lines indicate the cutoff for each assay.

Figure 2. SARS-CoV-2 spike specific T cell response during and after BNT162b2 mRNA-based SARS-CoV-2 vaccination regimen. The release of IFN-γ from stimulated $CD4^+$ T cells (A) and both $CD4^+$ and $CD8^+$ T cells (B) with SARS-CoV-2 spike peptides using QuantiFERON SARS-CoV-2 RUO. Box plots show median and two-thirds extended widths of IQR. Dots represent outliers (more/less than two-thirds of the extended widths of the IQR). Dashed lines indicate the cutoff for the assay.

Figure 3. Correlation between SARS-CoV-2 spike specific IgG titers and T cell responses at each time point. Spearman's rank correlation test was conducted using STATA version 17.0. (A) Correlation between IgG-S titer and spike-specific $CD4^+$ T-cell responses. (B) Correlation between IgG-S titer and spike-specific $CD4^+$ and $CD8^+$ T cell responses.

Table 1. Participants' characteristics (n = 100)

	Overall (n = 100)	
	Mean (SD)	**%**
Age, years	42.7 (11.7)	
<40		42
≥40		58
Sex		
Men		32
Women		68
Job category		
Doctors		7
Nurses		17
Allied healthcare professionals		4
Administrative staff		19
Others (e.g. researchers, research assistants)		53
Department		
COVID-19-related department		6
The other medical department		31
Non-medical department		63
Body mass index, kg/m^2	22.1 (3.2)	
<25		83
≥25		17

SD: standard deviation.

Table 2. Humoral and cellular immune responses during and after BNT162b2 mRNA-based SARS-CoV-2 vaccination regimen

	Days after First Vaccine Dose				
	Day 1 (n = 100)	**Day 15 (n = 100)**	**Day 29 (n = 97)**	**Day 61 (n = 97)**	**Day 82-96 (n = 96)**
IgG-S (AU/mL)	2.6 (1.45–4.40)	550* (277–1007)	20582*† (11711–29650)	9649*‡ (5189–13141)	5539*‡ (2954–8324)
Seropositive (≥50)	0%	99%	100%	100%	100%
Seropositive (≥4160)	0%	0%	96%	81%	59%
IgG-N (S/C)	0.07 (0.02–0.18)	0.07 (0.02–0.17)	0.08 (0.03–0.19)	0.05 (0.02–0.11)	0.07 (0.02–0.14)
Seropositive (≥1.40)	0%	0%	0%	0%	0%
IgM-S (S/C)	0.04 (0.03–0.08)	0.79* (0.45–1.44)	2.78*† (1.51–4.51)	0.75*‡ (0.48–1.52)	– –
Seropositive (≥1.00)	0%	43%	91%	40%	–
IFN-γ CD4$^+$ Ag2-Nil (IU/mL)	0.00 (-0.01–0.01)	0.85* (0.38–1.79)	5.40*† (3.00–10.4)	1.54*‡ (0.57–2.90)	– –
Positive (≥0.20)	0%	84%	100%	91%	–
IFN-γ CD4$^+$ and CD8$^+$ Ag1-Nil (IU/mL)	0.00 (-0.01–0.01)	1.72* (0.58–3.17)	9.40*† (5.20–16.4)	2.76*‡ (1.00–6.10)	– –
Positive (≥0.20)	0%	92%	100%	96%	–
NeutraLISA (Inhibition %)	– –	29* (14–45)	99*† (98–100)	98*‡ (98–99)	– –
Positive (≥35)	–	37%	100%	100%	–

Data are shown as median (interquartile range).

*: $P<0.01$ (Day 1 vs Day 15, 29 or 61 or 82–96)

†: $P<0.01$ (Day 15 vs Day 29)

‡: $P<0.01$ (Day 29 vs Day 61 or 82–96)

Table 3. Estimated geometric means with 95% confidence intervals of SARS-CoV-2 spike specific IgG titers by background factors

		Day 1		**Day 15**		**Day 29**		**Day 61**		**Day 82-96**		***P* for time**	***P* for groups**	***P* for interaction**
	N	**GMT**	**95% CI**	**GMT**	**95% CI**	**GMT**	**95% CI**	**GMT**	**95% CI**	**GMT**	**95% CI**			
Age <40	42	2.4	1.9–3.1	724.9	564–931*	22191	17109–28782	9363	7219–12144	5662	4407–7275	<0.01	<0.01	<0.01
Age ≥40	58	2.4	1.9–3.0	401.3	324–497*	15289	12353–18923	7048	5694–8723	3956	3190–4906			
Women	68	2.5	2.1–3.0	559.8	469–669	19631	16290–23658	8647	7063–10586	4936	3949–6169	<0.01	0.06	0.94
Men	32	2.2	1.6–2.8	427.3	330–554	14962	11445–19560	6816	5096–9117	3974	2862–5517			
BMI <25	83	2.4	2.0–2.9	537.6	448–645	18425	15324–22153	8086	6725–9722	4771	3977–5723	<0.01	0.43	0.98
BMI ≥25	17	2.2	1.5–3.3	415.1	278–621	14742	9738–22316	7026	4641–10635	3838	2535–5810			

Data are shown as geometric means with 95% confidence intervals estimated by the repeated measures mixed model.

All models were adjusted for age (<40 or ≥40 years) and sex.

*Significant differences between groups at each time point ($P<0.05$).

GMT: geometric mean titers.

Figure 1. Humoral responses during and after BNT162b2 mRNA-based SARS-CoV-2 vaccination regimen




C
20
10
1
.1
0
SARS-CoV-2 IgM (S/C)
Day 1
Day 15
Day 29
Day 61
Day 90


D
1.00
0.80
0.60
0.40
0.20
0.00
NeutraLISA (Inhibition %)
Day 1
Day 15
Day 29
Day 61
Day 90

Figure 2. SARS-CoV-2 spike specific T cell responses during and after BNT162b2 mRNA-based SARS-CoV-2 vaccination regimen



Figure 3. Correlation between SARS-CoV-2 spike specific IgG titers and T cell responses at each time point